Mohamed Shariff

660 total citations
16 papers, 482 citations indexed

About

Mohamed Shariff is a scholar working on Molecular Biology, Epidemiology and Hepatology. According to data from OpenAlex, Mohamed Shariff has authored 16 papers receiving a total of 482 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Molecular Biology, 8 papers in Epidemiology and 4 papers in Hepatology. Recurrent topics in Mohamed Shariff's work include Metabolomics and Mass Spectrometry Studies (8 papers), Liver Disease Diagnosis and Treatment (8 papers) and Cancer, Lipids, and Metabolism (3 papers). Mohamed Shariff is often cited by papers focused on Metabolomics and Mass Spectrometry Studies (8 papers), Liver Disease Diagnosis and Treatment (8 papers) and Cancer, Lipids, and Metabolism (3 papers). Mohamed Shariff collaborates with scholars based in United Kingdom, United States and Egypt. Mohamed Shariff's co-authors include Simon D. Taylor‐Robinson, Shahid A. Khan, Mary M.E. Crossey, I. Jane Cox, Andrew V. Thillainayagam, Howard C. Thomas, Nimzing G. Ladep, Horace R. Williams, Sabina Beg and Vijay P.B. Grover and has published in prestigious journals such as Gut, Hypertension and Journal of Hepatology.

In The Last Decade

Mohamed Shariff

14 papers receiving 476 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mohamed Shariff United Kingdom 11 210 171 146 93 63 16 482
Toshi Sassa Japan 8 104 0.5× 256 1.5× 377 2.6× 92 1.0× 31 0.5× 10 553
Hirotaka Takizawa Japan 12 166 0.8× 73 0.4× 29 0.2× 78 0.8× 29 0.5× 36 475
Xing Qi Teo Singapore 9 157 0.7× 67 0.4× 53 0.4× 48 0.5× 31 0.5× 11 380
Wei Geng China 11 175 0.8× 74 0.4× 58 0.4× 76 0.8× 15 0.2× 27 487
Tomoyuki Kubota Japan 15 411 2.0× 85 0.5× 104 0.7× 42 0.5× 18 0.3× 59 775
Jaimi L. Brown United States 7 275 1.3× 63 0.4× 25 0.2× 98 1.1× 45 0.7× 7 446
Yewei Liu China 11 112 0.5× 59 0.3× 49 0.3× 64 0.7× 105 1.7× 26 410
Masanori Seimiya Japan 12 114 0.5× 76 0.4× 43 0.3× 35 0.4× 18 0.3× 32 318
Michele Ruggiero Italy 7 119 0.6× 71 0.4× 110 0.8× 43 0.5× 9 0.1× 13 419
Alessandra Zullo Italy 6 123 0.6× 69 0.4× 109 0.7× 40 0.4× 9 0.1× 7 401

Countries citing papers authored by Mohamed Shariff

Since Specialization
Citations

This map shows the geographic impact of Mohamed Shariff's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mohamed Shariff with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mohamed Shariff more than expected).

Fields of papers citing papers by Mohamed Shariff

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mohamed Shariff. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mohamed Shariff. The network helps show where Mohamed Shariff may publish in the future.

Co-authorship network of co-authors of Mohamed Shariff

This figure shows the co-authorship network connecting the top 25 collaborators of Mohamed Shariff. A scholar is included among the top collaborators of Mohamed Shariff based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mohamed Shariff. Mohamed Shariff is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Shariff, Mohamed, et al.. (2021). Abstract P257: Refractory Hypertension Partially Improved With Anxiolytics. Hypertension. 78(Suppl_1).
2.
Shariff, Mohamed, Jin Un Kim, Nimzing G. Ladep, et al.. (2017). The Plasma and Serum Metabotyping of Hepatocellular Carcinoma in a Nigerian and Egyptian Cohort using Proton Nuclear Magnetic Resonance Spectroscopy. Journal of Clinical and Experimental Hepatology. 7(2). 83–92. 4 indexed citations
3.
Shariff, Mohamed, Jin Un Kim, Nimzing G. Ladep, et al.. (2016). Urinary Metabotyping of Hepatocellular Carcinoma in a UK Cohort Using Proton Nuclear Magnetic Resonance Spectroscopy. Journal of Clinical and Experimental Hepatology. 6(3). 186–194. 11 indexed citations
4.
Kim, Jin Un, Mohamed Shariff, Mary M.E. Crossey, et al.. (2016). Hepatocellular carcinoma: Review of disease and tumor biomarkers. World Journal of Hepatology. 8(10). 471–471. 59 indexed citations
5.
Beg, Sabina, et al.. (2016). Patient education and its effect on self-management in cirrhosis. European Journal of Gastroenterology & Hepatology. 28(5). 582–587. 33 indexed citations
6.
Sampaziotis, Fotios, William Gelson, Alexander Gimson, et al.. (2015). A retrospective study assessing fully covered metal stents as first-line management for malignant biliary strictures. European Journal of Gastroenterology & Hepatology. 27(11). 1347–1353. 10 indexed citations
7.
Shariff, Mohamed, Matthew R. Lewis, Elizabeth J. Want, et al.. (2015). Plasma Lipid Profiling in a Rat Model of Hepatocellular Carcinoma: Potential Modulation Through Quinolone Administration. Journal of Clinical and Experimental Hepatology. 5(4). 286–294. 10 indexed citations
8.
Shariff, Mohamed, Vijay P.B. Grover, Mary M.E. Crossey, et al.. (2015). Magnetic Resonance Spectroscopy: Principles and Techniques: Lessons for Clinicians. Journal of Clinical and Experimental Hepatology. 5(4). 320–328. 76 indexed citations
9.
Shariff, Mohamed, Shahid A. Khan, & David Westaby. (2013). The palliation of cholangiocarcinoma. Current Opinion in Supportive and Palliative Care. 7(2). 168–174. 13 indexed citations
10.
Shariff, Mohamed, Matthew R. Lewis, Hector C. Keun, et al.. (2012). PWE-264 Blood lipidomic profiling of hepatocellular carcinoma in human and animal studies identifies lysophosphatidylcholine (24, 0, 0), a discriminatory biomarker. Gut. 61(Suppl 2). A405.2–A405. 1 indexed citations
11.
Shariff, Mohamed, Matthew R. Lewis, Elizabeth J. Want, et al.. (2012). 748 BLOOD LIPIDOMIC PROFILING OF HEPATOCELLULAR CARCINOMA IN HUMAN AND ANIMAL STUDIES IDENTIFIES LYSOPHOSPHATIDYLCHOLINE (24, 0, 0) AS A DISCRIMINATORY BIOMARKER. Journal of Hepatology. 56. S294–S294. 1 indexed citations
12.
Shariff, Mohamed, Asmaa Gomaa, I. Jane Cox, et al.. (2011). Urinary Metabolic Biomarkers of Hepatocellular Carcinoma in an Egyptian Population: A Validation Study. Journal of Proteome Research. 10(4). 1828–1836. 82 indexed citations
13.
Shariff, Mohamed, Nimzing G. Ladep, Andrew V. Thillainayagam, et al.. (2010). Hepatocellular carcinoma: diagnostics and screening. Journal of Evaluation in Clinical Practice. 18(2). 335–342. 43 indexed citations
14.
Keane, Margaret G., et al.. (2009). Asymptomatic pericardial calcification in Whipple's disease. Journal of the Royal Society of Medicine. 102(11). 489–490.
15.
Ariff, Ben, Sameer Khan, Mohamed Shariff, et al.. (2009). Imaging of liver cancer. World Journal of Gastroenterology. 15(11). 1289–1289. 75 indexed citations
16.
Shariff, Mohamed, Nimzing G. Ladep, I. Jane Cox, et al.. (2009). Characterization of Urinary Biomarkers of Hepatocellular Carcinoma Using Magnetic Resonance Spectroscopy in a Nigerian Population. Journal of Proteome Research. 9(2). 1096–1103. 64 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026